drugset / Trial / NCT06922669

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

NCT06922669

RandomizedParallel-groupOpen-labelTreatment

Summary

Drug-induced liver injury (DILI) can lead to potentially fatal complications, such as acute liver failure and even death. In clinical practice, glucocorticoids have been considered in some cases of DILI, especially patients with hyperbilirubinemia. However, the available evidence remains controversial and its quality is also very limited. Herein, a multicenter randomized controlled trial (RCT) has been designed to explore the efficacy and safety of glucocorticoids in patients with acute DILI and hyperbilirubinemia.

Timeline

Start
2025-06-24
Primary completion
2027-03-31
Completion
2027-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylprednisolone Other / unclassified 40 mg Intravenous
Background Ademetionine Unknown 0.5 g
Background Ademetionine Unknown 1 g
Background Glutathione Peptide 1.2 g
Background Glutathione Peptide 1.8 g
Background Magnesium Isoglycyrrhizinate Unknown 0.15 g
Background Magnesium Isoglycyrrhizinate Unknown 0.2 g
Background Polyene Phosphatidylcholine Small molecule 228 mg
Background Polyene Phosphatidylcholine Small molecule 456 mg
Background Silymarin Traditional medicine (herbal / TCM) 140 mg
Background Ursodeoxycholic Acid Small molecule 10 mg/kg
Background Ursodeoxycholic Acid Small molecule 15 mg/kg